Bharat Biotech s Covaxin gets SEC approval for emergency use
The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter
BusinessToday.In | January 2, 2021 | Updated 23:57 IST
The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) has reportedly given its approval to Bharat Biotech s Covaxin coronavirus vaccine for emergency use. This makes it the second vaccine after Serum-AstraZeneca s Covishield to get marketing approval from the expert panel.
The SEC has recommended Covaxin for emergency use authorisation (EUA), reported news agency ANI quoting government sources. The recommendation, along with rollout modalities, will now be taken up by the Drug Controller General of India (DCGI) for a final decision on the matter.
New Delhi: The Subject Expert Committee of Central Drug Standard Control Organization Saturday recommended Bharat Biotech’s ‘Covaxin’ for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI).
The committee of experts assessing Coronavirus vaccines had called Hyderabad-based Bharat Biotech for a meeting in the afternoon today, a day after the firm was asked to present more data to get a nod, a top source said Saturday.
Friday, the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) had held that the data provided by Bharat Biotech for its Coronavirus vaccine is not sufficient for grant of emergency use approval and asked for more information.
COVID-19 vaccine will be free across India, says Dr Harsh Vardhan
India
Updated: Saturday, January 2, 2021, 13:05 [IST]
New Delhi, Jan 02: As the country is witnessing mass dry run across all the states and UTs and gearing up for the world s largest immunisation drive, Union Health Minister Harsh Vardhan said on Saturday that Covid-19 vaccine will be provided free of cost across the country.
Vaccines to be provided for free across India, says health min | Oneindia News
Dr Harsh Vardhan
While reviewing preparations for vaccine dry run in Delhi the Minister said to reporters, Not just in Delhi, it (vaccine) will be free across the country.
DCGI panel calls Bharat Biotech officials to meet over Covaxin vaccine today
India
Published: Saturday, January 2, 2021, 16:22 [IST]
New Delhi, Jan 02: A committee of experts assessing the coronavirus vaccines has called Hyderabad-based Bharat Biotech for a meeting on Saturday, a day after the firm was asked to present more data on its Covaxin to get the go-ahead, a top source said.
Representational Image
Earlier, the panel recommended emergency licensure for the Serum Institute of India s Covishield vaccine, making it the first in India to secure approval for emergency use.
However, nod of the Durg Controller General of India is, however, awaited on the recommendation.
COVID-19 expert panel recommends Bharat Biotech jab COVAXIN for emergency use authorisation The Subject Expert Committee (SEC) on COVID-19 of the CDSCO noted that the vaccine is an inactivated whole virion, coronavirus vaccine, having the potential to target mutated coronavirus strains, a source told PTI COVAXIN vaccine by Bharath Biotech.
New Delhi: An expert panel of India s central drug authority on Saturday recommended granting permission for the restricted use of Bharat Biotech-developed indigenous COVID-19 vaccine Covaxin in emergency situation, especially in the context of infection by mutant strains, officials said.
The recommendation for Bharat Biotech s vaccine came a day after the panel cleared the Serum Institute of India s emergency use athorisation application for the Oxford-AstraZeneca vaccine Covishield, paving the way for the roll-out of COVID-19